(Q57479582)

English

Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol (坎格列净，一种钠-葡萄糖共转运体2抑制剂，对血清1,5-脱水葡萄糖醇测定的影响)

No description defined

In more languages

Statements

scholarly article

0 references

Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol (坎格列净，一种钠-葡萄糖共转运体2抑制剂，对血清1,5-脱水葡萄糖醇测定的影响) (English)

0 references

author name string

Dainius A. Balis

1

0 references

Cindy Tong

2

0 references

Gary Meininger

3

0 references

publication date

25 February 2014

0 references

Journal of diabetes

0 references

6

0 references

4

0 references

378-380

0 references

Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12116

21 January 2018

Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12116

21 January 2018

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12116

21 January 2018

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12116

21 January 2018

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12116

21 January 2018

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12116

21 January 2018

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12116

21 January 2018

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12116

21 January 2018

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12116

21 January 2018

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12116

21 January 2018

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12116

21 January 2018

Identifiers

10.1111/1753-0407.12116

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57479582&oldid=1820002802"